| 0.8704 -0.14 (-13.82%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.42 |
1-year : | 1.71 |
| Resists | First : | 1.22 |
Second : | 1.47 |
| Pivot price | 1.17 |
|||
| Supports | First : | 0.82 |
Second : | 0.68 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.2 |
| MA(100) : | 1.5 |
MA(250) : | 7.56 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.4  |
D(3) : | 4.5 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 23.1 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GOVX ] has closed below the lower bollinger band by 13.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GOVX ] is to continue within current trading range. It is unclear right now based on current values. 55.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.97 - 0.98 | 0.98 - 0.98 |
| Low: | 0.81 - 0.82 | 0.82 - 0.82 |
| Close: | 0.86 - 0.87 | 0.87 - 0.88 |
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Thu, 16 Jul 2026
GOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurface - MSN
Fri, 10 Jul 2026
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
Fri, 10 Jul 2026
GeoVax Labs Received Notice of Noncompliance - TradingView
Fri, 10 Jul 2026
GeoVax Labs (NASDAQ: GOVX) flagged for Nasdaq $2.5M equity shortfall, delisting risk - Stock Titan
Fri, 03 Jul 2026
GOVX Should I Buy - Intellectia AI
Thu, 25 Jun 2026
GOVX Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.2e+006 (%) |
| Held by Institutions | 6.8 (%) |
| Shares Short | 584 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.144e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 523.4 % |
| Return on Equity (ttm) | -194.6 % |
| Qtrly Rev. Growth | 852280 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -138.77 |
| EBITDA (p.s.) | -4.31063e+006 |
| Qtrly Earnings Growth | -13.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 18.79 |
| Dividend | 0 |
| Forward Dividend | 62850 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|